Clinical Trial Search

Primary: Number of Local and Systemic Adverse Events (AEs) to Assess the Safety of the Study Drug — 34; 24; 23; 16 Adverse Events

Primary: Area Under the Plasma Concentration-time Profile From Time 0 the Last Quantifiable Concentration (AUC0-last) With Dose Normalization — 658; 700; 716; 748 pg.h/mL…

Primary: Adverse Events Related to BIO 300 Oral Powder — 0; 0; 0; 0 Number of Adverse Events

Primary: Dose-escalation: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs — 3; 3; 4; 3 Participants

Primary: Maximum Tolerated Dose (MTD) — 0; 0; 0; 0 DLTs

Primary: Glipizide Response as Measured by Area Over the Glucose Curve Between Time 0 and 240 Minutes According to Genotype — 4893.5; 5032.6; 6011 mg/dl x time(minutes)

Primary: Early Liver Stage: Number of Participants Over Time With Positive Parasitemia — 6; 3; 2; 1 Participants

Primary: Amygdala-PCC Functional Connectivity — -0.0815; -0.0530; -0.0456 z-score — p=.195

Primary: Rate of Completion — 7 Participants

Primary: Percentage of Participants Who Experienced at Least 1 Adverse Event (AE) — 33.3; 33.3; 33.3; 80.0 Percentage of Participants

Primary: The Number of Patients Who Demonstrate Pelvic Lymph Node Metastases on PSMA-PET/MRI That Were Not Detected on MRI — 3 Participants

Primary: Area Under the Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC[0-t]) for Niraparib-Stage 1 PK Phase — 14900; 16100…

Primary: Number of Patients Who Experienced Dose Limiting Toxicities (DLTs) — 0; 2; 0; 1 Participants

Primary: Number of Participants With First Cycle Dose-limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants

Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious (TEAEs) — 2; 2; 4; 2 Participants